Dr. Victoria Chua-Alcala, MD

About Victoria Chua-Alcala, MD

Education:

• Earned a Medical degree (MD) from an unspecified institution.

Experience:

• Serves as a clinical researcher at the Sarcoma Oncology Research Center.
• Involved in the GALLANT study (NCT04535713), a phase 2 clinical trial for advanced sarcoma.

Area of expertise

Affiliated Hospitals

Sarcoma Oncology Research Center

Sarcoma Oncology Center

Clinical Trials Victoria Chua-Alcala, MD is currently running

Chemotherapy + Immunotherapy

for Advanced Sarcoma

This trial uses a combination of chemotherapy and immunotherapy to treat patients with advanced sarcoma. The chemotherapy attacks the cancer directly, while the immunotherapy boosts the body's natural defenses to help fight the cancer.

Recruiting1 award Phase 212 criteria

Bria-OTS Immunotherapy

for Breast Cancer

This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.

Recruiting1 award Phase 1 & 27 criteria

More about Victoria Chua-Alcala, MD

Other Doctors you might be interested in

Frequently asked questions